Accumulating evidence suggests that myeloid-derived suppressor cells (MDSCs) underpin an immunological checkpoint that is activated during inflammation or "inflammatory-like" conditions like cancer. Here, we discuss the identification of MDSCs in patients receiving allogeneic hematopoietic stem cell transplantation and their potential as therapeutic targets or tools for improving the efficacy of this treatment.
No takes yet. Share an insight, caveat, or question.
Blanc et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: